Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Oct. 31, 2003

By Aaron Lorenzo

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today)

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Oct. 31, 2003

By Aaron Lorenzo

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Oct. 31, 2003

By Aaron Lorenzo

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Oct. 31, 2003

By Aaron Lorenzo

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today)

Guilford Gains U.S. Rights To Cardiovascular Product

Oct. 30, 2003

By Aaron Lorenzo

Guilford Gains U.S. Rights To Cardiovascular Product

Oct. 30, 2003

By Aaron Lorenzo

Avera In-Licenses From Novartis Anxiety, Depression Compound

Oct. 29, 2003

By Aaron Lorenzo

Avera In-Licenses From Novartis Anxiety, Depression Compound

Oct. 29, 2003

By Aaron Lorenzo

Remicade's Phase III Data Support Label Expansion In Spinal Arthritis

Oct. 28, 2003

By Aaron Lorenzo

Remicade's Phase III Data Support Label Expansion In Spinal Arthritis

Oct. 28, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.